Merck acquires JSR Life Sciences chromatography business
Strengthens its downstream process offering with the addition of JSR’s Amsphere Protein A resin technology.
List view / Grid view
Strengthens its downstream process offering with the addition of JSR’s Amsphere Protein A resin technology.
The pharma company invested $445m to expand its Coppell site.
Regulator classifies former Catalent site as ‘official action indicated’, impacting biotech clients such as Regeneron.
Gains US-based operations with its new Phoenix, Arizona injectable drug product manufacturing and packaging site.
The company will now put a total of $4.5 billion into the Virginia site, expanding its remit to include active pharmaceutical ingredients for cancer drugs.
Sets bioequivalence and active pharmaceutical ingredient (API) requirements for its new ANDA prioritisation programme.
Establishes Resource for AI Science in Europe and eyes frontier AI models and autonomous agentic AI for pharma.
The investment will cover CMO collaborations and a new manufacturing and quality hub in Hyderabad.
He joins the US company with over two decades of experience in pharma operations, supply chain and manufacturing.
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
The pharma company’s plan to divest its active pharmaceutical ingredient interests was first announced in 2024.
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
Pharma manufacturing facility construction placed at the heart of a policy announcement made on social media.
As other pharma companies reconsider their investments, Moderna’s focus insulates it from the UK’s drug pricing row.
This whitepaper provides a detailed examination of Lonza’s holistic, data-driven approach to CCI, developed in collaboration with industry experts and applied across our global network for parenteral combination products.